Treace Medical Concepts, Inc. Stock
Equities
TMCI
US89455T1097
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.740 USD | 0.00% |
|
-8.05% | -63.17% |
| Capitalization | 175M 150M 141M 131M 242M 15.71B 263M 1.64B 635M 7.42B 655M 641M 27.13B | P/E ratio 2025 * |
-2.92x | P/E ratio 2026 * | -3.24x |
|---|---|---|---|---|---|
| Enterprise value | 172M 148M 138M 129M 238M 15.47B 259M 1.62B 625M 7.31B 645M 631M 26.71B | EV / Sales 2025 * |
0.81x | EV / Sales 2026 * | 0.88x |
| Free-Float |
75.16% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Treace Medical Concepts, Inc.
More recommendations
More press releases
| 1 week | -8.05% | ||
| Current month | -8.05% | ||
| 1 month | -56.02% | ||
| 3 months | -61.79% | ||
| 6 months | -52.84% | ||
| Current year | -63.17% |
| 1 week | 2.63 | 3.03 | |
| 1 month | 2.56 | 4.81 | |
| Current year | 2.56 | 10.79 | |
| 1 year | 2.56 | 10.79 | |
| 3 years | 2.56 | 27.97 | |
| 5 years | 2.56 | 37.17 | |
| 10 years | 2.56 | 37.17 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Treace
CEO | Chief Executive Officer | 53 | 2013-06-30 |
Mark Hair
DFI | Director of Finance/CFO | 55 | 2020-08-31 |
Taylor Erickson
CTO | Chief Tech/Sci/R&D Officer | - | 2022-02-28 |
| Director | Title | Age | Since |
|---|---|---|---|
John Treace
CHM | Chairman | 53 | 2025-05-19 |
John Bakewell
BRD | Director/Board Member | 63 | 2020-11-19 |
| Director/Board Member | 67 | 2020-11-19 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | -8.05% | -65.45% | -88.53% | 175M | ||
| -0.01% | +0.01% | +0.01% | +43.87% | 12.57B | ||
| +2.02% | +2.55% | +26.74% | +39.19% | 11.77B | ||
| -0.41% | -0.53% | -16.56% | +2.19% | 7.61B | ||
| +0.24% | -1.72% | +23.33% | -11.22% | 6.11B | ||
| -0.03% | +4.60% | +16.12% | +23.83% | 5.23B | ||
| -0.14% | +1.23% | +6.67% | +2.64% | 5.1B | ||
| -0.17% | +3.12% | -8.84% | +74.99% | 4.82B | ||
| +0.05% | -.--% | +56.56% | +14.67% | 4.7B | ||
| -1.00% | -5.18% | +54.01% | -12.40% | 2.01B | ||
| Average | +0.06% | -0.86% | +9.26% | +8.92% | 6.01B | |
| Weighted average by Cap. | +0.31% | +0.43% | +12.82% | +24.77% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 212M 182M 171M 159M 294M 19.07B 320M 2B 771M 9.01B 795M 778M 32.93B | 214M 184M 173M 161M 297M 19.28B 323M 2.02B 779M 9.11B 804M 787M 33.29B |
| Net income | -59.21M -50.9M -47.68M -44.44M -82.09M -5.33B -89.28M -558M -215M -2.52B -222M -217M -9.2B | -54.24M -46.63M -43.68M -40.71M -75.2M -4.88B -81.79M -511M -197M -2.31B -204M -199M -8.43B |
| Net Debt | -2.72M -2.34M -2.19M -2.04M -3.77M -245M -4.1M -25.62M -9.89M -116M -10.21M -9.99M -423M | 13.98M 12.02M 11.26M 10.5M 19.39M 1.26B 21.09M 132M 50.86M 594M 52.49M 51.37M 2.17B |
More financial data
* Estimated data
Employees
477
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 2.740 $ | 0.00% | 613,791 |
| 25-12-04 | 2.740 $ | +2.24% | 733,622 |
| 25-12-03 | 2.680 $ | -0.74% | 682,693 |
| 25-12-02 | 2.700 $ | -4.59% | 591,710 |
| 25-12-01 | 2.830 $ | -5.03% | 738,113 |
Delayed Quote Nasdaq, December 05, 2025 at 04:00 pm EST
More quotesSell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
2.740USD
Average target price
5.470USD
Spread / Average Target
+99.64%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TMCI Stock
Select your edition
All financial news and data tailored to specific country editions
















